FindTrial
Sign In

Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-527114-23-00
Enrollment
12
Registered
2026-08-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

Change from Baseline in standardized photosensitivity range (SPR) on pre-dose Day 1 (placebo) to post-dose OV329 on several days

Interventions

DRUGOV329
DRUGPlacebo for OV329

Sponsors

Ovid Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change from Baseline in standardized photosensitivity range (SPR) on pre-dose Day 1 (placebo) to post-dose OV329 on several days—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 4, 2026